Expression Profile of the Polycomb Group Protein Enhancer of Zeste Homologue 2 and its Prognostic Relevance in Renal Cell Carcinoma
is companion of
Abstract
Purpose:
EZH2 increases the proliferation rate and apoptosis resistance of renal cell carcinoma cell lines. To date its clinical impact on the outcome in patients with renal cell carcinoma is not known. To our knowledge this is the first study of the association of EZH2 expression with histopathological features and disease outcomes in a large cohort of patients who underwent surgery for renal cell carcinoma.
Materials and Methods:
Real-time reverse transcriptase-polymerase chain reaction was done to quantify EZH2 expression in malignant and adjacent benign renal tissue from a cohort of 119 patients with clear cell renal cell carcinoma. Median followup was 51 months. Immunohistochemistry was performed in a subset of samples. The impact of EZH2 expression on clinicopathological tumor features and outcome was investigated.
Results:
EZH2 was over expressed in renal cell carcinoma compared to adjacent benign renal parenchyma (median 57.02, range 0 to 368.11 vs 0, range 0 to 280.87, p <0.001). Immunohistochemistry showed concordant results and revealed EZH2 protein predominantly located in the nucleus. EZH2 expression was not associated with histopathological tumor features and patient characteristics. High EZH2 levels predicted a lower disease recurrence rate on univariate and multivariate analysis (p = 0.047 and 0.037, respectively).
Conclusions:
These data support a role of EZH2 expression for renal cell carcinoma tumorigenesis rather than tumor progression. Contrary to previous EZH2 findings in cases of various human malignancies, high tumor EZH2 levels appear to indicate less aggressive tumor phenotypes with a favorable prognosis in renal cell carcinoma cases. Our findings suggest that EZH2 provides not only a potential therapeutic target, but also a molecular parameter for outcome prediction in patients with renal cell carcinoma.
References
- 1 : Cancer statistics, 2008. CA Cancer J Clin2008; 58: 71. Google Scholar
- 2 : Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol2008; 179: 2146. Link, Google Scholar
- 3 : Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol2000; 163: 1090. Link, Google Scholar
- 4 : Renal-cell carcinoma. N Engl J Med1996; 335: 865. Google Scholar
- 5 : Polycomb, epigenomes, and control of cell identity. Cell2003; 112: 599. Google Scholar
- 6 : Translating the histone code. Science2001; 293: 1074. Google Scholar
- 7 : Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell2002; 111: 197. Google Scholar
- 8 : EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol2006; 24: 268. Google Scholar
- 9 : EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J2003; 22: 5323. Google Scholar
- 10 : Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol2007; 177: 1229. Link, Google Scholar
- 11 : The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature2002; 419: 624. Google Scholar
- 12 : The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia2005; 7: 1011. Google Scholar
- 13 : The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer2008; 123: 1545. Google Scholar
- 14 : TNM classification of malignant tumors. New York: John Wiley & Sons2002. Google Scholar
- 15 : Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res2008; 647: 21. Google Scholar
- 16 : Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res2007; 67: 5083. Google Scholar
- 17 : Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol2008; 29: 323. Google Scholar
- 18 : Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol1997; 17: 6076. Google Scholar
- 19 : EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res2008; 10: R109. Google Scholar
- 20 : Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol2007; 177: 1157. Link, Google Scholar
- 21 : Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate2004; 60: 273. Google Scholar
Department of Urology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin and Department of Pathology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
